Page 68 - Read Online

Liu et al. Developing treatment guidance for myasthenia gravis

Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth gravis. Neuroimmunol Neuroinflammation 2016;3:1-9.
SG, Wiendl H. Clinical features, pathogenesis, and treatment of 16. Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based
myasthenia gravis: a supplement to the Guidelines of the German on its immunopathogenesis. J Clin Neurol 2011;7:173-83.
Neurological Society. J Neurol 2016;263:1473-94. 17. Feng HY, Liu WB, Qiu L, Huang X, Huang RX. Analysis of prognostic
8. Murai H. Japanese clinical guidelines for myasthenia gravis: putting factors and efficacy of plasmapheresis in the treatment of myastheniac
into practice. Clin Exp Neuroimmunol 2015;6:21-31. crisis. Zhonghua Yi Xue Za Zhi 2010;90:3343-6.
9. Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton- 18. Liu WB, Men LN, Tang BY, Huang RX. Prognostic factors
Jones D. Myasthenia gravis: association of British Neurologists’ of myasthenic crisis after extended thymectomy in patients
management guidelines. Pract Neurol 2015;15:199-206. with generalized myasthenia gravis. Zhonghua Yi Xue Za Zhi
10. Norwood F, Dhanjal M, Hill M, James N, Jungbluth H, Kyle P, 2006;86:2737-40.
O’Sullivan G, Palace J, Robb S, Williamson C, Hilton-Jones D, 19. Wang HY, Su Z, Luo CM, Li Y, Feng HY, Fang W, Du CY, Deng J, Yu
Nelson-Piercy C. Myasthenia in pregnancy: best practice guidelines F, Liu WB. The effect of steroid treatment and thymectomy on bone
from a UK multispecialty working group. J Neurol Neurosurg age and height development in juvenile myasthenia gravis. Neurol Sci
Psychiatry 2014;85:538-43. 2013;34:2173-80.
11. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton- 20. Li Y, Liu WB, Luo CM, Feng HY, Huang X, Wang HY, Qiu L, Huang
Jones D, Melms A, Verschuuren J, Horge HW; European Federation RX. Response to thymectomy and analysis of influencing factors in
of Neurological Societies. Guidelines for treatment of autoimmune the treatment of children with myasthenia gravis. Zhonghua Yi Xue Za
neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902. Zhi 2012;92:1170-3.
12. Li Y, Chen P, Ding L, Luo C, Wang H, Chen Z, Su C, Feng H, Huang X, 21. Chen ZG, Zuo JD, Zou JY, Sun YH, Liu WB, Lai YR, Zhong BL,
Xia W, Liu W. Clinical outcome and predictive factors of irradiation- Su CH, Tan M, Luo HH. Cellular immunity following video-assisted
associated myasthenia gravis exacerbation in thymomatous patients. thoracoscopic and open resection for non-thymomatous myasthenia
Neurol Sci 2015;36:2121-7. gravis. Eur J Cardiothorac Surg 2014;45:646-51.
13. Feng HY, Wang HY, Liu WB, He XT, Huang X, Luo CM, Li Y. The 22. Liu W, He XT, Zhang Y, Huang RX. Prognostic factors related to
high frequency and clinical feature of seronegative myasthenia gravis recurrence after extended thymectomy in patients with myasthenia
in Southern China. Neurol Sci 2013;34:919-24. gravis. Zhonghua Yi Xue Za Zhi 2008;88:1446-9.
14. Liu Z, Feng H, Yeung SC, Zheng Z, Liu W, Ma J, Zhong FT, Luo 23. Liu WB, Men LN, Chen ZG, Luo HH, Huang RX. Long-term efficacy
H, Cheng C. Extended transsternal thymectomy for the treatment of of enlarged thymectomy in treatment of myasthenia gravis and
ocular myasthenia gravis. Ann Thorac Surg 2011;92:1993-9. relevant influencing factors: study of 410 cases. Zhonghua Yi Xue Za
15. Li ZY. China guidelines for the diagnosis and treatment of myasthenia Zhi 2006;86:3182-5.

60 Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ March 30, 2017